Efficacy of bromocriptine in the treatment of metastatic breast cancer- and prostate cancer-related hyperprolactinemia

P. Lissoni, M. Mandala, L. Giani, F. Malugani, S. Secondino, S. Zonato, F. Rocco, G. Gardani

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Objective: Hyperprolactinemia is a frequent evidence occurring in both metastatic breast cancer and prostate cancer, and it has been proven to be associated with poor prognosis and reduced efficacy of the anticancer therapies. Therefore, the pharmacological control of cancer-related hyperprolactinemia could improve the prognosis of advanced breast and prostate carcinomas. Unfortunately, at present it is still controversial which may be the treatment of cancer-related hyperprolactinemia, which could depend at least in part on a direct autocrine production by cancer cells themselves. The present study was performed to evaluate the acute effects of the long-acting dopaminergic agonist bromocriptine on cancer-related hyperprolactinemia. Methods: The study included 10 women affected by metastatic breast cancer and 10 men with metastatic prostate cancer, showing persistent hyperprolactinemia. Venous blood samples were collected before bromocriptine, and 2, 4, 10 and 24 hours after bromocriptine administration (2.5 mg orally) serum levels of PRL were measured with the double antibody RIA method. Results: Bromocriptine induced a normalization of PRL levels in both groups of patients with breast and prostate cancers. Moreover, mean levels of PRL persisted significantly lower than those found before therapy during the whole 24-hour circadian period. Discussion: This preliminary study shows that low-dose bromocriptine is sufficient to acutely normalize PRL secretion in both metastatic breast cancer and prostate carcinoma patients, irrespectively of the mechanisms involved in inducing cancer-related hyperprolactinemia. Therefore, low-dose bromocriptine could be recommended in association with the classical antitumor therapies in the treatment of metastatic breast cancer and prostate carcinoma patients showing cancer-related hyperprolactinemia, in an attempt to improve the efficacy of anticancer therapies themselves.

Original languageEnglish
Pages (from-to)405-408
Number of pages4
JournalNeuroendocrinology Letters
Volume21
Issue number5
Publication statusPublished - 2000

Fingerprint

Hyperprolactinemia
Bromocriptine
Prostatic Neoplasms
Breast Neoplasms
Neoplasms
Therapeutics
Carcinoma
Second Primary Neoplasms
Dopamine Agonists
Prostate
Pharmacology
Antibodies
Serum

Keywords

  • Breast cancer
  • Hyperpolactinemia
  • Prolactin
  • Prostate cancer

ASJC Scopus subject areas

  • Endocrinology
  • Neuroscience(all)

Cite this

Lissoni, P., Mandala, M., Giani, L., Malugani, F., Secondino, S., Zonato, S., ... Gardani, G. (2000). Efficacy of bromocriptine in the treatment of metastatic breast cancer- and prostate cancer-related hyperprolactinemia. Neuroendocrinology Letters, 21(5), 405-408.

Efficacy of bromocriptine in the treatment of metastatic breast cancer- and prostate cancer-related hyperprolactinemia. / Lissoni, P.; Mandala, M.; Giani, L.; Malugani, F.; Secondino, S.; Zonato, S.; Rocco, F.; Gardani, G.

In: Neuroendocrinology Letters, Vol. 21, No. 5, 2000, p. 405-408.

Research output: Contribution to journalArticle

Lissoni, P, Mandala, M, Giani, L, Malugani, F, Secondino, S, Zonato, S, Rocco, F & Gardani, G 2000, 'Efficacy of bromocriptine in the treatment of metastatic breast cancer- and prostate cancer-related hyperprolactinemia', Neuroendocrinology Letters, vol. 21, no. 5, pp. 405-408.
Lissoni, P. ; Mandala, M. ; Giani, L. ; Malugani, F. ; Secondino, S. ; Zonato, S. ; Rocco, F. ; Gardani, G. / Efficacy of bromocriptine in the treatment of metastatic breast cancer- and prostate cancer-related hyperprolactinemia. In: Neuroendocrinology Letters. 2000 ; Vol. 21, No. 5. pp. 405-408.
@article{1fcf5586b0954522860c4464ba462c5b,
title = "Efficacy of bromocriptine in the treatment of metastatic breast cancer- and prostate cancer-related hyperprolactinemia",
abstract = "Objective: Hyperprolactinemia is a frequent evidence occurring in both metastatic breast cancer and prostate cancer, and it has been proven to be associated with poor prognosis and reduced efficacy of the anticancer therapies. Therefore, the pharmacological control of cancer-related hyperprolactinemia could improve the prognosis of advanced breast and prostate carcinomas. Unfortunately, at present it is still controversial which may be the treatment of cancer-related hyperprolactinemia, which could depend at least in part on a direct autocrine production by cancer cells themselves. The present study was performed to evaluate the acute effects of the long-acting dopaminergic agonist bromocriptine on cancer-related hyperprolactinemia. Methods: The study included 10 women affected by metastatic breast cancer and 10 men with metastatic prostate cancer, showing persistent hyperprolactinemia. Venous blood samples were collected before bromocriptine, and 2, 4, 10 and 24 hours after bromocriptine administration (2.5 mg orally) serum levels of PRL were measured with the double antibody RIA method. Results: Bromocriptine induced a normalization of PRL levels in both groups of patients with breast and prostate cancers. Moreover, mean levels of PRL persisted significantly lower than those found before therapy during the whole 24-hour circadian period. Discussion: This preliminary study shows that low-dose bromocriptine is sufficient to acutely normalize PRL secretion in both metastatic breast cancer and prostate carcinoma patients, irrespectively of the mechanisms involved in inducing cancer-related hyperprolactinemia. Therefore, low-dose bromocriptine could be recommended in association with the classical antitumor therapies in the treatment of metastatic breast cancer and prostate carcinoma patients showing cancer-related hyperprolactinemia, in an attempt to improve the efficacy of anticancer therapies themselves.",
keywords = "Breast cancer, Hyperpolactinemia, Prolactin, Prostate cancer",
author = "P. Lissoni and M. Mandala and L. Giani and F. Malugani and S. Secondino and S. Zonato and F. Rocco and G. Gardani",
year = "2000",
language = "English",
volume = "21",
pages = "405--408",
journal = "Neuroendocrinology Letters",
issn = "0172-780X",
publisher = "Maghira and Maas Publications",
number = "5",

}

TY - JOUR

T1 - Efficacy of bromocriptine in the treatment of metastatic breast cancer- and prostate cancer-related hyperprolactinemia

AU - Lissoni, P.

AU - Mandala, M.

AU - Giani, L.

AU - Malugani, F.

AU - Secondino, S.

AU - Zonato, S.

AU - Rocco, F.

AU - Gardani, G.

PY - 2000

Y1 - 2000

N2 - Objective: Hyperprolactinemia is a frequent evidence occurring in both metastatic breast cancer and prostate cancer, and it has been proven to be associated with poor prognosis and reduced efficacy of the anticancer therapies. Therefore, the pharmacological control of cancer-related hyperprolactinemia could improve the prognosis of advanced breast and prostate carcinomas. Unfortunately, at present it is still controversial which may be the treatment of cancer-related hyperprolactinemia, which could depend at least in part on a direct autocrine production by cancer cells themselves. The present study was performed to evaluate the acute effects of the long-acting dopaminergic agonist bromocriptine on cancer-related hyperprolactinemia. Methods: The study included 10 women affected by metastatic breast cancer and 10 men with metastatic prostate cancer, showing persistent hyperprolactinemia. Venous blood samples were collected before bromocriptine, and 2, 4, 10 and 24 hours after bromocriptine administration (2.5 mg orally) serum levels of PRL were measured with the double antibody RIA method. Results: Bromocriptine induced a normalization of PRL levels in both groups of patients with breast and prostate cancers. Moreover, mean levels of PRL persisted significantly lower than those found before therapy during the whole 24-hour circadian period. Discussion: This preliminary study shows that low-dose bromocriptine is sufficient to acutely normalize PRL secretion in both metastatic breast cancer and prostate carcinoma patients, irrespectively of the mechanisms involved in inducing cancer-related hyperprolactinemia. Therefore, low-dose bromocriptine could be recommended in association with the classical antitumor therapies in the treatment of metastatic breast cancer and prostate carcinoma patients showing cancer-related hyperprolactinemia, in an attempt to improve the efficacy of anticancer therapies themselves.

AB - Objective: Hyperprolactinemia is a frequent evidence occurring in both metastatic breast cancer and prostate cancer, and it has been proven to be associated with poor prognosis and reduced efficacy of the anticancer therapies. Therefore, the pharmacological control of cancer-related hyperprolactinemia could improve the prognosis of advanced breast and prostate carcinomas. Unfortunately, at present it is still controversial which may be the treatment of cancer-related hyperprolactinemia, which could depend at least in part on a direct autocrine production by cancer cells themselves. The present study was performed to evaluate the acute effects of the long-acting dopaminergic agonist bromocriptine on cancer-related hyperprolactinemia. Methods: The study included 10 women affected by metastatic breast cancer and 10 men with metastatic prostate cancer, showing persistent hyperprolactinemia. Venous blood samples were collected before bromocriptine, and 2, 4, 10 and 24 hours after bromocriptine administration (2.5 mg orally) serum levels of PRL were measured with the double antibody RIA method. Results: Bromocriptine induced a normalization of PRL levels in both groups of patients with breast and prostate cancers. Moreover, mean levels of PRL persisted significantly lower than those found before therapy during the whole 24-hour circadian period. Discussion: This preliminary study shows that low-dose bromocriptine is sufficient to acutely normalize PRL secretion in both metastatic breast cancer and prostate carcinoma patients, irrespectively of the mechanisms involved in inducing cancer-related hyperprolactinemia. Therefore, low-dose bromocriptine could be recommended in association with the classical antitumor therapies in the treatment of metastatic breast cancer and prostate carcinoma patients showing cancer-related hyperprolactinemia, in an attempt to improve the efficacy of anticancer therapies themselves.

KW - Breast cancer

KW - Hyperpolactinemia

KW - Prolactin

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=0033785634&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033785634&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0033785634

VL - 21

SP - 405

EP - 408

JO - Neuroendocrinology Letters

JF - Neuroendocrinology Letters

SN - 0172-780X

IS - 5

ER -